What is the initial treatment approach for a patient diagnosed with Myasthenia Gravis?

Initial Treatment Approach for Myasthenia Gravis

Begin with pyridostigmine 30 mg orally three times daily as first-line symptomatic therapy, titrating upward based on clinical response to a maximum of 120 mg four times daily. 1, 2, 3

Diagnostic Confirmation Before Treatment

• Confirm diagnosis with acetylcholine receptor (AChR) antibodies and antistriated muscle antibodies in blood 1, 2
• If AChR antibodies are negative, test for muscle-specific kinase (MuSK) and lipoprotein-related protein 4 (LRP4) antibodies 1, 2
• Perform electrodiagnostic studies including repetitive nerve stimulation and/or single-fiber EMG (>90% sensitivity for ocular myasthenia) 4
• Assess baseline pulmonary function with negative inspiratory force (NIF) and vital capacity (VC) 5, 1

Stepwise Treatment Algorithm

Mild Disease (Grade 1: Ocular symptoms only or minimal weakness)

• Start pyridostigmine 30 mg orally three times daily 1, 2
• Gradually increase dose every 3-5 days based on symptom response 1
• Maximum dose: 120 mg four times daily 1, 2, 3
• Monitor closely for progression, as 50-80% of patients with initial ocular symptoms will develop generalized disease within a few years 4, 2

Moderate Disease (Grade 2: Some interference with activities of daily living)

• Continue or optimize pyridostigmine dosing 1, 2
• Add corticosteroids if pyridostigmine provides insufficient control: prednisone 0.5-1.5 mg/kg orally daily 5, 1, 2
• Approximately 66-85% of patients respond positively to corticosteroids 4, 2
• Taper steroids gradually over 4-6 weeks based on symptom improvement 5, 1

Severe Disease (Grade 3-4: Myasthenic crisis with respiratory compromise, severe generalized weakness, dysphagia, or rapidly progressive symptoms)

• Permanently discontinue any triggering medications and admit to ICU immediately 5, 1
• Initiate IVIG 2 g/kg IV over 5 days (0.4 g/kg/day) OR plasmapheresis for 5 days 5, 1, 2
• Continue high-dose corticosteroids: methylprednisolone 1-2 mg/kg daily 5, 1
• Continue pyridostigmine unless intubation is required 1, 2
• Perform frequent pulmonary function assessments with NIF and VC monitoring 5, 1, 2
• Conduct daily neurologic evaluations 5, 1

Critical Medications to Avoid

Educate all patients to strictly avoid these medications that worsen myasthenic symptoms: 5, 1, 2

• β-blockers 5, 1, 2
• Intravenous magnesium 5, 1, 2
• Fluoroquinolone antibiotics 5, 1, 2
• Aminoglycoside antibiotics 5, 1, 2
• Macrolide antibiotics 5, 1, 2
• Metoclopramide 1

Important Clinical Pitfalls

• Do NOT use IVIG for chronic maintenance therapy - it is reserved only for acute exacerbations or crisis situations 1
• Approximately 50% of patients with ocular myasthenia show minimal response to pyridostigmine alone and will require corticosteroid escalation 4
• Pupils are characteristically NOT affected in myasthenia gravis - if pupillary abnormalities are present, immediately consider alternative diagnoses such as third nerve palsy 4
• Sequential therapy with plasmapheresis followed by IVIG is no more effective than either treatment alone and should be avoided 1
• In pregnant women, IVIG may be preferred over plasmapheresis due to fewer monitoring requirements 1, 2

Monitoring and Follow-up

• Regular neurologic consultation to adjust treatment as needed 1
• Ongoing pulmonary function assessment, especially in patients with generalized disease or respiratory symptoms 5, 1, 2
• Monitor for disease progression from ocular to generalized myasthenia 4, 2
• Consider thymectomy evaluation in appropriate candidates with AChR antibody-positive generalized MG up to age 65 years 6, 7